Juno Therapeutics, A Subsidiary Of Celgene

This early-stage trial tested a new treatment called CC-95266 in 130 adults with multiple myeloma that had come back or stopped responding to other therapies. The main goals were to check safety, find the right dose, and see if the treatment could shrink the cancer. While not a c…